Strategic International Retreat: McKesson has completed its exit from Canadian retail operations (December 2024) and is divesting Norwegian operations, signaling a deliberate pullback from international markets with potential near-term impairment risks but likely focus on core North American operations. Margin Pressure from Restructuring: Continued "Strategic Growth Initiative" restructuring…

Our analysis rates this filing NEUTRAL. The elevated concern level (5.5/10) reflects a balanced but cautiously optimistic picture. While McKesson faces meaningful operational challenges—including systematic international market withdrawal, ongoing restructuring costs, and significant opioid…

Concern level: ELEVATED (5.5/10). Key factors: Risk score of 7.8/10 with INCREASING trend indicates mounting operational challenges; Multiple international market exits (Canadian retail completed, Norwegian operations held for sale) represent strategic retreat and potential asset impairment losses; Ongoing restructuring charges under Strategic Growth Initiative suggest persistent margin pressure…

Notable risk changes: McKesson completed exit from Canadian retail operations (December 2024) and has Norwegian operations held for sale, representing systematic international market withdrawal and potential asset impairment losses; Ongoing restructuring charges under 'Strategic Growth Initiative' indicate persistent operational challenges requiring cost optimization across multiple segments, suggesting margin…

Q2 adjusted EPS of $7.07 exceeded analyst consensus estimates; Total revenues of $93.7B in Q2 beat expectations driven by strong pharmaceutical distribution volumes; Adjusted operating profit growth of 18% YoY significantly outperformed expectations.

The model predicts MCK will outperform the S&P 500 by about 0.0% over 30 days. This is model analysis for research, not investment advice.